230 related articles for article (PubMed ID: 12190308)
1. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Cavalli A; Poluzzi E; De Ponti F; Recanatini M
J Med Chem; 2002 Aug; 45(18):3844-53. PubMed ID: 12190308
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.
Kongsamut S; Kang J; Chen XL; Roehr J; Rampe D
Eur J Pharmacol; 2002 Aug; 450(1):37-41. PubMed ID: 12176106
[TBL] [Abstract][Full Text] [Related]
3. Molecular determinants of high-affinity drug binding to HERG channels.
Mitcheson JS; Perry MD
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):667-74. PubMed ID: 14579516
[TBL] [Abstract][Full Text] [Related]
4. A structural basis for drug-induced long QT syndrome.
Mitcheson JS; Chen J; Lin M; Culberson C; Sanguinetti MC
Proc Natl Acad Sci U S A; 2000 Oct; 97(22):12329-33. PubMed ID: 11005845
[TBL] [Abstract][Full Text] [Related]
5. Predicting drug-hERG channel interactions that cause acquired long QT syndrome.
Sanguinetti MC; Mitcheson JS
Trends Pharmacol Sci; 2005 Mar; 26(3):119-24. PubMed ID: 15749156
[TBL] [Abstract][Full Text] [Related]
6. QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development.
Recanatini M; Poluzzi E; Masetti M; Cavalli A; De Ponti F
Med Res Rev; 2005 Mar; 25(2):133-66. PubMed ID: 15389727
[TBL] [Abstract][Full Text] [Related]
7. Zebrafish embryos express an orthologue of HERG and are sensitive toward a range of QT-prolonging drugs inducing severe arrhythmia.
Langheinrich U; Vacun G; Wagner T
Toxicol Appl Pharmacol; 2003 Dec; 193(3):370-82. PubMed ID: 14678746
[TBL] [Abstract][Full Text] [Related]
8. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
[TBL] [Abstract][Full Text] [Related]
9. In silico modelling--pharmacophores and hERG channel models.
Recanatini M; Cavalli A; Masetti M
Novartis Found Symp; 2005; 266():171-81; discussion 181-5. PubMed ID: 16050268
[TBL] [Abstract][Full Text] [Related]
10. Characterisation of recombinant HERG K+ channel blockade by the Class Ia antiarrhythmic drug procainamide.
Ridley JM; Milnes JT; Benest AV; Masters JD; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2003 Jun; 306(2):388-93. PubMed ID: 12804575
[TBL] [Abstract][Full Text] [Related]
11. Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes.
Witchel HJ; Milnes JT; Mitcheson JS; Hancox JC
J Pharmacol Toxicol Methods; 2002; 48(2):65-80. PubMed ID: 14565563
[TBL] [Abstract][Full Text] [Related]
12. QT interval prolongation and cardiac risk assessment for novel drugs.
Picard S; Lacroix P
Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
[TBL] [Abstract][Full Text] [Related]
13. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG.
Rampe D; Murawsky MK; Grau J; Lewis EW
J Pharmacol Exp Ther; 1998 Aug; 286(2):788-93. PubMed ID: 9694935
[TBL] [Abstract][Full Text] [Related]
14. Class III antiarrhythmic drugs block HERG, a human cardiac delayed rectifier K+ channel. Open-channel block by methanesulfonanilides.
Spector PS; Curran ME; Keating MT; Sanguinetti MC
Circ Res; 1996 Mar; 78(3):499-503. PubMed ID: 8593709
[TBL] [Abstract][Full Text] [Related]
15. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics.
Volberg WA; Koci BJ; Su W; Lin J; Zhou J
J Pharmacol Exp Ther; 2002 Jul; 302(1):320-7. PubMed ID: 12065733
[TBL] [Abstract][Full Text] [Related]
16. [Preclinical evaluation of drug induced QT prolongation].
Hashimoto K
Nihon Yakurigaku Zasshi; 2003 Jun; 121(6):408-10. PubMed ID: 12899128
[No Abstract] [Full Text] [Related]
17. Prediction of hERG K+ blocking potency: application of structural knowledge.
Aptula AO; Cronin MT
SAR QSAR Environ Res; 2004; 15(5-6):399-411. PubMed ID: 15669698
[TBL] [Abstract][Full Text] [Related]
18. Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine.
Scholz EP; Zitron E; Kiesecker C; Lueck S; Kathöfer S; Thomas D; Weretka S; Peth S; Kreye VA; Schoels W; Katus HA; Kiehn J; Karle CA
Naunyn Schmiedebergs Arch Pharmacol; 2003 Nov; 368(5):404-14. PubMed ID: 14557918
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel.
Ekins S; Crumb WJ; Sarazan RD; Wikel JH; Wrighton SA
J Pharmacol Exp Ther; 2002 May; 301(2):427-34. PubMed ID: 11961040
[TBL] [Abstract][Full Text] [Related]
20. Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652.
Milnes JT; Crociani O; Arcangeli A; Hancox JC; Witchel HJ
Br J Pharmacol; 2003 Jul; 139(5):887-98. PubMed ID: 12839862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
